01117nas a2200133   4500000000100000008004100001260001200042100001200054700001500066700001200081245006500093520081100158022001400969       2024                            d  c05/20241 aAdler B1 aHarnisch J1 aOchoa M00aLeprosy-Insufficient Evidence for Monthly Multidrug Therapy.3 a<p><strong>To the Editor</strong>&nbsp;In the recent case report by Poondru et al,&nbsp;a patient with lepromatous leprosy was treated with monthly multidrug antibiotic therapy (rifampin, moxifloxacin, and minocycline) following consultation with the US National Hansen’s Disease Program (NHDP). The patient also initiated treatment with methotrexate and prednisone “to reduce the risk of erythema nodosum leprosum.”<sup><a href="https://jamanetwork.com/journals/jamadermatology/article-abstract/2819416#dle240006r1">1</a></sup>&nbsp;On behalf of several US leprosy experts, we are concerned about the lack of evidence supporting these treatment recommendations, which diverge from published NHDP guidelines recommending daily antibiotic therapy with the possible exception of monthly rifampin.</p>
  a2168-6084